The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection

• Published in: Progress in drug research Vol. 50; p. 259
• Main Authors: Colacino, J M, Staschke, K A
• Format: Journal Article
• Language: English
• Published: Switzerland 1998
• Subjects: Animals; Antiviral Agents - therapeutic use; Disease Models, Animal; Drug Therapy, Combination; Hepatitis B virus - ultrastructure; Hepatitis B, Chronic - drug therapy; Humans; Virus Replication - drug effects
• ISSN: 0071-786X
• DOI: 10.1007/978-3-0348-8833-2_6

Hepatitis B virus (HBV) is the leading cause of chronic hepatitis throughout the world. Notwithstanding the availability of a safe and effective vaccine, the world prevalence of HBV has not declined significantly, thus resulting in the need for a selective antiviral agent. HBV is a small, partially double-stranded DNA virus which replicates through an RNA intermediate. Most efforts to develop anti-HBV agents have been targeted to the viral DNA polymerase which possesses reverse transcriptase activity. Currently, the most promising anti-HBV agents are nucleoside analogs which interfere with viral DNA replication. Although earlier nucleoside analogs such as vidarabine (ara-A) and fialuridine (FIAU) have displayed unacceptable toxicities, newer analogs such as lamivudine (3TC), bis-POM PMEA (GS-840), lobucavir, and BMS-200,475 have demonstrated clinical utility. In particular, the use of lamivudine has generated considerable interest in the development of other L-enantiomeric nucleoside analogs for use against HBV. Here, we provide an overview of HBV structure and replication strategy and discuss the use of cell culture systems, in vitro viral polymerase systems, and animal models to identify and evaluate anti-HBV agents. We also discuss the various classes of nucleoside analogs in terms of structure, mechanism of action, status in clinical development, ability to select for resistant HBV variants, and use in combination therapies. Finally, we present a discussion of novel antiviral approaches, including antisense and gene therapy, and address the various challenges to successful anti-HBV chemotherapeutic intervention.